SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN THE STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No.)*

Enzon Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, par value \$0.01 per share (Title of Class of Securities)

> 293904108 (CUSIP Number)

March 5, 2014 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

□ Rule 13d-1(b) ⊠ Rule 13d-1(c)

 \Box Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

F							
1	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)						
	Stonepine Capital, L.P.						
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP						
	(a) ⊠ (b) □						
3	SEC USE ONLY						
4	CITIZENSHIP OR PLACE OF ORGANIZATION						
	Califorr						
		5	SOLE VOTING POWER				
NUMBEI	P OF		0				
SHARI	ES	6	SHARED VOTING POWER				
BENEFICI OWNED			4.200,000 Shares of Common Stock(1)				
EACI	H	7	SOLE DISPOSITIVE POWER				
REPORT PERSC			0				
WITH	I	8	SHARED DISPOSITIVE POWER				
			4.200.000 Shares of Common Stock ⁽¹⁾				
9	AGGRE	EGA	TE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	4 200 0	00.0					
10	4,200,000 Shares of Common Stock ⁽¹⁾ CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES						
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)						
	TERCENT OF CLASS REFRESENTED BT AMOUNT IN ROW (2)						
12	9.5%(2) TWDE OF DEDOD TING DED SON						
12	TYPE OF REPORTING PERSON						
	PN						
-							

(2) The calculation of percentage of beneficial ownership was derived from the issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2013, in which the issuer stated that the number of shares of its common stock outstanding as of November 1, 2013 was 44,068,299.

 $2 \ of 8$

1							
1	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)						
	Stonepine Capital Management, LLC						
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP						
	(a) ⊠ (b) □						
3	SEC USE ONLY						
4	CITIZENSHIP OR PLACE OF ORGANIZATION						
	California						
		5	SOLE VOTING POWER				
NUMBEI	R OF		0				
SHARI BENEFICI		6	SHARED VOTING POWER				
OWNED	BY	7	4,200,000 Shares of Common Stock(1) SOLE DISPOSITIVE POWER				
REPORT	TING	/	SOLE DISPOSITIVE POWER				
PERSC WITH		8	0 SHARED DISPOSITIVE POWER				
		0					
9	AGGRE	EGA	4,200,000 Shares of Common Stock ⁽¹⁾ TE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON				
	4 200 0	00.9	Sharas of Common Stock(1)				
10	4,200,000 Shares of Common Stock(1) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES						
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)						
	9.5%(2)						
12	TYPE OF REPORTING PERSON						
	HC						

(2) The calculation of percentage of beneficial ownership was derived from the issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2013, in which the issuer stated that the number of shares of its common stock outstanding as of November 1, 2013 was 44,068,299.

3 of 8

-								
1	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)							
	Jon M. Plexico							
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP							
	(a) ⊠ (b) □							
3	SEC USE ONLY							
4	CITIZENSHIP OR PLACE OF ORGANIZATION							
United States of America								
	5 SOLE VOTING POWER							
NUMBE								
SHAR	ES 6 SHARED VOTING POWER							
BENEFICI OWNED								
EACI	H 7 SOLE DISPOSITIVE POWER							
REPORT PERSC								
WITH	8 SHARED DISPOSITIVE POWER							
	4.200.000 Shares of Common Stock ⁽¹⁾							
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON							
	4.200.000 Shares of Common Stock ⁽¹⁾							
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES							
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)							
12	9.5%(2) TYPE OF REPORTING PERSON							
	IN							

(2) The calculation of percentage of beneficial ownership was derived from the issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2013, in which the issuer stated that the number of shares of its common stock outstanding as of November 1, 2013 was 44,068,299.

1	NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (Entities Only)							
	Timothy P. Lynch							
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP							
	(a) ⊠ (b) □							
3	SEC USE ONLY							
4	CITIZENSHIP OR PLACE OF ORGANIZATION							
United States of America								
	5 SOLE VOTING POWER							
NUMBE SHAR	ES 6 SHARED VOTING POWER							
BENEFICI OWNED								
EACI	I 7 SOLE DISPOSITIVE POWER							
REPORT PERSC								
WITH	8 SHARED DISPOSITIVE POWER							
	4.200,000 Shares of Common Stock ⁽¹⁾							
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON							
10	4,200,000 Shares of Common Stock ⁽¹⁾ CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES							
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)							
12	9.5%(2) TYPE OF REPORTING PERSON							
12	I ITE OF KEFOKTING FEKSON							
	IN							

(2) The calculation of percentage of beneficial ownership was derived from the issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 12, 2013, in which the issuer stated that the number of shares of its common stock outstanding as of November 1, 2013 was 44,068,299.

5 of 8

Item 1(a).	Name of Issuer:			
	Enzon Pharmaceuticals, Inc. (the "Issuer")			
Item 1(b).	Address of Issuer's Principal Executive Offices: Enzon Pharmaceuticals, Inc. 20 Kingsbridge Road Piscataway, New Jersey 08854			
Items 2(a), 2(b) and 2(c)	Name of Person Filing, Address of Principal Business Office and Citizenship:			
	This Schedule 13G Amendment 1 (this "Schedule") is being filed on behalf of Stonepine Capital, L.P., Stonepine Capital Management, LLC, Jon M. Plexico and Timothy P. Lynch (collectively, the "Reporting Persons").			
	The Reporting Persons have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule as Exhibit 1, pursuant to which the Reporting Persons have agreed to file this Schedule jointly in accordance with the provisions of Rule 13d-1(k) of the Securities Exchange Act of 1934, as amended.			
	The principal business office of the Reporting Persons is:			
	c/o Stonepine Capital Management, LLC 475 Gate Five Road, Suite 320 Sausalito CA 94965			
Item 2(d).	Title of Class of Securities:			
	Common Stock, par value \$0.01 per share (the "Common Stock")			
Item 2(e).	CUSIP Number:			
	293904108			
Item 3.	Not applicable			
Item 4.	Ownership.			
	(a) <u>Amount beneficially owned</u> : 4,200,000 shares of common stock ⁽¹⁾			
	(b) Percent of class: 9.5%(1)			
	(c) <u>Number of shares to which such person has</u> :			
	(i) Sole power to vote or direct the vote: 0			
	(ii) Shared power to vote or direct the vote: 4,200,000 shares of common stock. (1)			

(iii) Sole power to dispose or to direct the disposition of: $\mathbf{0}$

(iv) Shared power to dispose of or direct the disposition of: 4,200,000 shares of common stock(1) (1) Reference is hereby made to Items 5-9 and 11 of pages 2-5 of this Schedule, which Items are incorporated by reference herein. The total number of securities (the "Securities") reported on this Schedule includes shares of the issuer's common stock that have been issued to Stonepine Capital, L.P. as of March 5, 2014. Stonepine Capital Management, LLC is the general partner of Stonepine Capital, L.P., and therefore may be deemed to be the beneficial owner of the Securities beneficially owned by Stonepine Capital, L.P. Jon M. Plexico and Timothy P. Lynch are the managing members of Stonepine Capital Management and may be deemed to be the beneficial owners of the Securities held by Stonepine Capital, L.P. as they may direct the vote and disposition of such Securities. Each of Messrs. Plexico and Lynch disclaim beneficial ownership of these Securities except to the extent of their respective pecuniary interest therein. Item 5. Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following \Box . Item 6. Ownership of More than Five Percent on Behalf of Another Person. Not applicable Identification and Classification of the Subsidiary Which Acquired the Security Being Reported By the Parent Holding Company. Item 7. Not applicable Item 8. Identification and Classification of Members of the Group. This statement is filed on behalf of Stonepine Capital, L.P., Stonepine Capital Management, LLC, Jon M. Plexico and Timothy P. Lynch. Stonepine Capital Management, LLC is the general partner of Stonepine Capital, L.P., and therefore may be deemed to be the beneficial owner of the Securities beneficially owned by Stonepine Capital, L.P. Jon M. Plexico and Timothy P. Lynch are the managing members of Stonepine Capital Management and may be deemed to be the beneficial owners of the Securities held by Stonepine Capital, L.P. as they may direct the vote and disposition of such Securities. Item 9. Notice of Dissolution of a Group.

Not applicable

Item 10. Certification.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: March 13, 2014

STONEPINE CAPITAL, L.P.

By:	/s/ Jo	n M	. Plex	ico			
Name:	Jon M	M. Pl	exico	,			
					0.0	1.0	

Title: Managing Member of General Partner

STONEPINE CAPITAL MANAGEMENT, LLC

By:	/s/ Jon M. Plexico
Name:	Jon M. Plexico
Title:	Managing Member

/s/ Jon M. Plexico Jon M. Plexico

/s/ Timothy P. Lynch Timothy P. Lynch

JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to certain shares of common stock of Enzon Pharmaceuticals, Inc. and further agree that this Joint Filing Agreement shall be included as an exhibit to such joint filings.

The undersigned further agree that each party hereto is responsible for the timely filing of such Schedule 13G and any amendments thereto, and for the completeness and accuracy of the information concerning such party contained therein; provided, however, that no party is responsible for the completeness or accuracy of the information concerning any other party making the filing, unless such party knows or has reason to believe that such information is inaccurate.

IN WITNESS WHEREOF, the parties have executed this Joint Filing Agreement on March 13, 2014.

STONEPINE CAPITAL, L.P.

 By:
 /s/ Jon M. Plexico

 Name:
 Jon M. Plexico

 Title:
 Managing Member of General Partner

STONEPINE CAPITAL MANAGEMENT, LLC

By: /s/ Jon M. Plexico

Name: Jon M. Plexico Title: Managing Member

/s/ Jon M. Plexico Jon M. Plexico

/s/ Timothy P. Lynch

Timothy P. Lynch